<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615550</url>
  </required_header>
  <id_info>
    <org_study_id>COL-1620-302</org_study_id>
    <secondary_id>09-CH-N014</secondary_id>
    <nct_id>NCT00615550</nct_id>
  </id_info>
  <brief_title>PREGNANT Short Cervix Trial</brief_title>
  <official_title>The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy for Short Cervix - Trial (PREGNANT Short Cervix - Trial)]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juniper Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Juniper Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel
      in decreasing the preterm birth rate in a population of pregnant women with short cervical
      length and at high risk for preterm birth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Short uterine cervical length in the mid-trimester is the most powerful predictor of
      preterm birth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Birth &lt;=32 6/7 Weeks Gestation.</measure>
    <time_frame>9 to 13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Neonatal Morbidities Such as Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH), Proven Sepsis, and Necrotizing Enterocolitis (NEC)</measure>
    <time_frame>Delivery Hospitalization (1-212 days)</time_frame>
    <description>Each infant is scored based on the 7 morbidity and mortality events above:
0= no morbidity event
1 morbidity event
2 morbidity events
3 or more morbidity events
mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Preterm Birth at ≤27 6/7, ≤34 6/7, and &lt;36 6/7 Weeks Gestation.</measure>
    <time_frame>Gestational Age at Delivery</time_frame>
    <description>Number of participants at &lt;=27 6/7 , &lt;=34 6/7, and &lt;36 6/7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Who Died.</measure>
    <time_frame>Delivery to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With a Birth Weight &lt; 1500 Grams or &lt; 2500 Grams</measure>
    <time_frame>date of delivery</time_frame>
    <description>Assessment of birth weight &lt; 1500 grams or &lt; 2500 grams</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">465</enrollment>
  <condition>Preterm Delivery</condition>
  <condition>Short Cervix</condition>
  <condition>Short Uterine Cervical Length</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo vaginal gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prochieve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Progesterone 8% Vaginal Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation</description>
    <arm_group_label>Prochieve</arm_group_label>
    <other_name>Prochieve 8%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has a short cervical length by transvaginal ultrasound (TVU) defined as
             10-20mm. In cases of &quot;dynamic cervix&quot;, the shortest observed/documented cervical
             length by TVU is to be used as the cervical length for inclusion purposes.

          2. Singleton gestation.

          3. The pregnancy has an estimated gestational age between 19 0/7 weeks and 23 6/7 weeks.

          4. Maternal age between 15 (or local age of majority/emancipation) and 45 years of age at
             the time of screening. An alternative age range can be accepted according to the
             standards and applicable regulations of the study centers.

          5. The subject speaks either English or a common local language.

          6. The subject has voluntarily signed the Informed Consent Form and associated forms
             after having the contents explained, and all her questions are answered to her
             satisfaction and understanding.

          7. In the opinion of the investigator, the subject is able to understand the study and is
             able to give informed consent, as well as participate in it and adhere to study
             procedures.

        Exclusion Criteria:

          1. The subject has a cervical length &lt;10 or &gt;20mm.

          2. The subject has a multifetal gestation.

          3. The subject has or is scheduled to have a cervical cerclage prior to randomization.
             According to ACOG Practice Bulletin Number 48 (November 2003), cerclage can be
             considered in a subject with a history of 3 or more unexplained midtrimester pregnancy
             losses or preterm deliveries.228,229

          4. Subjects diagnosed to have acute cervical insufficiency with bulging membranes passing
             the external os.

          5. The subject has a previous history of an adverse reaction to progesterone or any
             component present in Prochieve® 8% vaginal gel.

          6. The subject has been treated with a progestogen within the previous 4 weeks.

          7. The subject is currently being treated for a seizure disorder, has an unstable
             psychiatric disorder, is taking antihypertensive therapy for chronic hypertension at
             the time of enrollment, has a history of congestive heart failure or chronic renal
             failure, or has uncontrolled diabetes mellitus (known end-organ dysfunction secondary
             to vascular disease).

          8. The subject has active thrombophlebitis or a thromboembolic disorder, or a history of
             hormone-associated thrombophlebitis or thromboembolic disorders.

          9. The subject has active liver dysfunction or disease.

         10. The subject has known or suspected malignancy of the breast or genital organs.

         11. The subject is currently participating in another interventional study or has
             participated in an interventional drug study within one month prior to screening for
             this study.

         12. The subject's current pregnancy is complicated by a major fetal anomaly or known
             chromosomal abnormality.

         13. The subject has a uterine anatomic malformation (bicornuate uterus, septate uterus)

         14. The subject, in the judgment of the investigator, will be unable or unwilling to
             comply with study-related assessments and procedures.

         15. The subject currently has preterm rupture of membranes, vaginal bleeding, known or
             suspected amnionitis, or signs or symptoms of preterm labor at the time of enrollment.

         16. The subject is HIV positive with a CD4 count of &lt;350 cells/mm3 and is receiving more
             than one (1) medication to prevent the transfer of AIDS to the fetus.

         17. Complete placenta previa.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George W. Creasy, MD, FACOG</last_name>
    <role>Study Director</role>
    <affiliation>Columbia Laboratories, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Romero, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Hassan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Dept. of OB/GYN</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Med Ctr Women's Care Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Leonard Miller School of Medicine Department of Obstetrics and Gynecology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapi'olani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal Center of Iowa</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal Diagnostic Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Community Physicians</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatology Research Branch Hutzel Women's Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Healthcare System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Research Department</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy-Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Dept. of OB/GYN</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Health Sciences Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hosital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPHS Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-6130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital OB/GYN / Maternal Fetal Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Obstetrical Consultants, Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Obstetrical Consultants, Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center Clinical Trials Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Clinical Hospital of the City of Minsk</name>
      <address>
        <city>Minsk</city>
        <zip>22004</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Health Services Establishment &quot;Vitebsk City Clinical Hospital of First Aid&quot;</name>
      <address>
        <city>Vitebsk</city>
        <zip>210009</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escuela De Medicina, Pontificia Universidad Catolica De Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternidad Hospital DR Sotero Del Rio</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University &amp; General Teaching Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BJ Medical College &amp; Sassoon Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Ramchandra Medical College and Research Institute</name>
      <address>
        <city>Porur</city>
        <state>Tamil Nadu</state>
        <zip>600003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheth L.G. Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediCiti Institute of Medical Sciences</name>
      <address>
        <city>Andhra Pradesh</city>
        <zip>5014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College</name>
      <address>
        <city>Nagpur</city>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84965</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>58291</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova Centro Prenatale Divisione di Ostetricia</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;American Health Clinic&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Healthcare Institution Maternity Hospital 17</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192174</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Biko Academic Hospital Dept. of OB-GYN and Maternal Fetal Medicine</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal health care establishment &quot;City Maternity Clinical Hospital&quot;</name>
      <address>
        <city>Chernovtsy</city>
        <zip>58001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology of Dnepropetrovsk State Medical Academy, Municipal establishment &quot;City Maternity Hospital # 1&quot;</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. Gorky Donetsk National Medical University, Department of Obstetrics, Gynecology and Perinatology, Maternity Hospital of 6th Central City Clinical Hospital</name>
      <address>
        <city>Donetsk</city>
        <zip>83062</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal clinical hospital #1</name>
      <address>
        <city>Kiev</city>
        <zip>2175</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antenatal Clinic # 1, Central Polyclinics of Pechersk District</name>
      <address>
        <city>Kyiv</city>
        <zip>01042</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www3.interscience.wiley.com/cgi-bin/fulltext/116322931/PDFSTART</url>
    <description>[Trial Results] Progesterone vaginal gel for the reduction of recurrent preterm birth (free download)</description>
  </link>
  <link>
    <url>http://www3.interscience.wiley.com/cgi-bin/fulltext/116322930/PDFSTART</url>
    <description>Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix (free download)</description>
  </link>
  <link>
    <url>http://content.nejm.org/cgi/content/short/357/5/462</url>
    <description>Progesterone and the Risk of Preterm Birth among Women with a Short Cervix (free download)</description>
  </link>
  <link>
    <url>http://www3.interscience.wiley.com/cgi-bin/fulltext/116323485/PDFSTART</url>
    <description>Prevention of sponatneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. (free download)</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/uog.9017/pdf</url>
    <description>Ultrasound Obstet Gynecol (2011)</description>
  </link>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/uog.9017/pdf</url>
    <description>Open Access to Final Study Result Publication</description>
  </link>
  <link>
    <url>http://www.ajog.org/article/S0002-9378(11)02358-1/fulltext</url>
    <description>[Individual Patient Data Meta-analysis] Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data</description>
  </link>
  <reference>
    <citation>O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Soma-Pillay P, Porter K, How H, Schackis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007 Oct;30(5):687-96.</citation>
    <PMID>17899572</PMID>
  </reference>
  <reference>
    <citation>DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Soma-Pillay P, Porter K, How H, Schakis R, Eller D, Trivedi Y, Vanburen G, Khandelwal M, Trofatter K, Vidyadhari D, Vijayaraghavan J, Weeks J, Dattel B, Newton E, Chazotte C, Valenzuela G, Calda P, Bsharat M, Creasy GW. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007 Oct;30(5):697-705.</citation>
    <PMID>17899571</PMID>
  </reference>
  <reference>
    <citation>Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007 Aug 2;357(5):462-9.</citation>
    <PMID>17671254</PMID>
  </reference>
  <reference>
    <citation>Romero R. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. Ultrasound Obstet Gynecol. 2007 Oct;30(5):675-86.</citation>
    <PMID>17899585</PMID>
  </reference>
  <results_reference>
    <citation>Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW; PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011 Jul;38(1):18-31. doi: 10.1002/uog.9017. Epub 2011 Jun 15.</citation>
    <PMID>21472815</PMID>
  </results_reference>
  <results_reference>
    <citation>Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012 Feb;206(2):124.e1-19. doi: 10.1016/j.ajog.2011.12.003. Epub 2011 Dec 11. Review.</citation>
    <PMID>22284156</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <results_first_submitted>February 24, 2012</results_first_submitted>
  <results_first_submitted_qc>February 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2012</results_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preterm</keyword>
  <keyword>Cervix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>March 2008 to June 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo vaginal gel</description>
        </group>
        <group group_id="P2">
          <title>Prochieve</title>
          <description>Progesterone 8% Vaginal Gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo vaginal gel</description>
        </group>
        <group group_id="B2">
          <title>Prochieve</title>
          <description>Progesterone 8% Vaginal Gel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
            <count group_id="B2" value="235"/>
            <count group_id="B3" value="458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.1"/>
                    <measurement group_id="B2" value="26.5" spread="5.8"/>
                    <measurement group_id="B3" value="26.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Birth &lt;=32 6/7 Weeks Gestation.</title>
        <time_frame>9 to 13 weeks</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo vaginal gel</description>
          </group>
          <group group_id="O2">
            <title>Prochieve</title>
            <description>Progesterone 8% Vaginal Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Birth &lt;=32 6/7 Weeks Gestation.</title>
          <population>Intent to Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Neonatal Morbidities Such as Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH), Proven Sepsis, and Necrotizing Enterocolitis (NEC)</title>
        <description>Each infant is scored based on the 7 morbidity and mortality events above:
0= no morbidity event
1 morbidity event
2 morbidity events
3 or more morbidity events
mortality</description>
        <time_frame>Delivery Hospitalization (1-212 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo vaginal gel</description>
          </group>
          <group group_id="O2">
            <title>Prochieve</title>
            <description>Progesterone 8% Vaginal Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Neonatal Morbidities Such as Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH), Proven Sepsis, and Necrotizing Enterocolitis (NEC)</title>
          <description>Each infant is scored based on the 7 morbidity and mortality events above:
0= no morbidity event
1 morbidity event
2 morbidity events
3 or more morbidity events
mortality</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite score 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite score 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite score 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite score 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite score 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infants with RDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented for composite score data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented for RDS data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Preterm Birth at ≤27 6/7, ≤34 6/7, and &lt;36 6/7 Weeks Gestation.</title>
        <description>Number of participants at &lt;=27 6/7 , &lt;=34 6/7, and &lt;36 6/7.</description>
        <time_frame>Gestational Age at Delivery</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo vaginal gel</description>
          </group>
          <group group_id="O2">
            <title>Prochieve</title>
            <description>Progesterone 8% Vaginal Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Preterm Birth at ≤27 6/7, ≤34 6/7, and &lt;36 6/7 Weeks Gestation.</title>
          <description>Number of participants at &lt;=27 6/7 , &lt;=34 6/7, and &lt;36 6/7.</description>
          <population>Intent to Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of deliveries &lt;= 27 6/7 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of deliveries &lt;= 34 6/7 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of deliveries &lt;= 36 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented for births &lt;=27 6/7 weeks data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented for &lt;= 34 6/7 weeks data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis presented for &lt;36 weeks data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Who Died.</title>
        <time_frame>Delivery to 28 days</time_frame>
        <population>All infants with a known delivery date and status.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo vaginal gel</description>
          </group>
          <group group_id="O2">
            <title>Prochieve</title>
            <description>Progesterone 8% Vaginal Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Who Died.</title>
          <population>All infants with a known delivery date and status.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.431</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With a Birth Weight &lt; 1500 Grams or &lt; 2500 Grams</title>
        <description>Assessment of birth weight &lt; 1500 grams or &lt; 2500 grams</description>
        <time_frame>date of delivery</time_frame>
        <population>Available birth weight.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo vaginal gel</description>
          </group>
          <group group_id="O2">
            <title>Prochieve</title>
            <description>Progesterone 8% Vaginal Gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With a Birth Weight &lt; 1500 Grams or &lt; 2500 Grams</title>
          <description>Assessment of birth weight &lt; 1500 grams or &lt; 2500 grams</description>
          <population>Available birth weight.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Birth weight &lt; 1500 grams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Birth weight &lt; 2500 grams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for birth weight &lt; 1500 grams data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for birth weight &lt; 2500 grams data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.213</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to delivery (1 day to 168 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo vaginal gel</description>
        </group>
        <group group_id="E2">
          <title>Prochieve</title>
          <description>Progesterone 8% Vaginal Gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain lower</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecysitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>ureaplasma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>abdominal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>feotal monitoring</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>gestational diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>premature baby</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="224"/>
                <counts group_id="E2" events="44" subjects_affected="44" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>premature labor</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="224"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>premature rupture of the membranes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>uterine contractions abnormal</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>foetal distress abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>cervical incompetence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>pre-eclampsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>stillbirth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>chorioamnionitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>foetal growth retardation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>pregnancy induced hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>premature separation of placenta</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>foetal heart rate deceleration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>intra-uterine death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>funisitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>oligohydramnios</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>HELLP syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>bradycardia foetal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>breech presentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>cholestasis of pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>foetal movements decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>obstructed labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>placenta accreta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>tachycardia foetal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>umbilical cord prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>vomiting in pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>cervix disorder</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="224"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>uterine pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>physical assault</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>cervix cerclage procedure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>maternal therapy to enhance foetal lung maturity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="223"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="223"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>gestational diabetes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="223"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="223"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Bleeding peripartum</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Vomiting in pregnancy</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>chorioamnionitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="223"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>premature rupture of membranes</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="223"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>foetal growth retardation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="223"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>cervix disorder</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="223"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial not powered for subgroup analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>George W Creasy MD</name_or_title>
      <organization>Columbia Laboratories</organization>
      <phone>973-486-8797</phone>
      <email>Gcreasy@columbialabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

